What Should I Do When the DEA Shows Up at My Pharmacy?

What Should I Do When the DEA Shows Up at My Pharmacy?

The Piece of Paper That Ends Careers

The form they present you is not an invitation. It is DEA Form 82, the Notice of Inspection of Controlled Premises, and the six rights printed on its face are the last constitutional protections you will possess before the inspection commences. Most pharmacists sign it within minutes. The ones who read it, if we are being precise, not a majority, discover something the investigator will not emphasize: item two on that form confirms you may refuse.

A diversion investigator arriving at your pharmacy counter on a Thursday afternoon carries with them the authority of Title 21 of the Code of Federal Regulations, Part 1316, and something less formal but more consequential: the expectation that you will cooperate. They have been trained to manage that moment. You have not. The asymmetry is the point.

What the form authorizes, once signed, is total access. Records, personnel, files, inventory, the contents of your dispensing software, the prescriptions arranged behind the counter. There is no partial consent. There is no provision to say “this drawer but not that one.” The signature opens every door in the building, and once given, it cannot be retrieved. Consent, under 21 CFR 1316.06, is an all or nothing proposition, and nothing about the investigator’s demeanor will communicate that fact with the weight it deserves.

A pharmacist in Richmond, Texas signed that form in 2024. Mariste Pharmacy’s registration was suspended the same day. The Order to Show Cause alleged imminent danger to public health. The pharmacy never reopened.

Six rights appear on the document. The right against warrantless administrative inspection. The right to refuse. The right to a Notice of Inspection. The right to consent without coercion. The right to withdraw that consent at any point during the inspection. And the sixth, the one that matters most: any incriminating evidence discovered may be seized and used in criminal prosecution.

That last provision is printed on the form itself. The DEA tells you, in writing, before you sign, that what they find can put you in a federal courtroom. Most pharmacists sign it anyway.

I have yet to determine whether this reflects trust in the system or exhaustion with it.

Refusal Is Not Obstruction

The instinct to cooperate is professional. Pharmacists are trained to answer questions, to explain procedures, to be transparent with regulatory bodies. That training, in the context of a DEA inspection, becomes a liability.

Refusing to sign Form 82 is a constitutional right. The form itself says so. The investigator may suggest otherwise. They may tell you they will return with a warrant. This is probably true. Administrative inspection warrants do not require probable cause, and courts grant them routinely. The DEA will come back. But what refusal purchases is time (approximately one to two weeks, depending on the district, and in that interval you may consult with counsel, conduct a privileged internal audit, review your dispensing records under the protection of attorney client privilege, and prepare your staff for the questions that will follow).

The calculus depends on your position. If your compliance records are current, if your biennial inventory reconciles, if your red flag documentation meets the standard the DEA now requires, consent may be the sounder strategy. Courts have noted that refusal can appear suspicious in subsequent proceedings, though they are obligated to acknowledge it as a right. Where compliance deficiencies exist, where your attorney has not yet reviewed your dispensing patterns, refusal is not excessive caution. It is ordinary prudence.

And here is what no one mentions at the pharmacy conferences: the investigator standing at your counter has spent weeks reviewing your PDMP data, your distributor records, your prescribing volume, before walking through the door. The visit is not random. The form says it might be. It is not.

Cooperation Builds the Case Against You

The most dangerous assumption a pharmacist can make during a DEA inspection is that helpfulness will be credited. It will not. Over cooperation, volunteering information the investigator did not request, explaining practices they did not ask about, produces a result opposite to what the pharmacist intends. You do not know what the investigation concerns. The Controlled Substances Act contains prohibitions both specific and nonspecific to pharmaceutical practice. Information offered in the spirit of transparency about one matter can open an inquiry into another the DEA had not considered.

Do not obstruct. Do not interfere with investigators performing their work. But the distance between obstruction and cooperation is wider than most pharmacists appreciate, and the safest position is squarely in the center of it.

Corresponding Responsibility Is Personal

The doctrine that governs every controlled substance prescription you dispense does not attach to your pharmacy. It attaches to you. Under the corresponding responsibility standard, a pharmacist carries an independent, nondelegable duty to determine that each prescription for a controlled substance has been issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. You cannot attribute the decision to a technician’s intake. You cannot shelter behind a corporate dispensing protocol. The responsibility is yours, and it follows you home.

In 2024, the DEA revoked Coconut Grove Pharmacy’s registration in South Florida after finding the pharmacy had failed to identify, resolve, and document the resolution of red flags associated with controlled substance prescriptions. The critical detail in the administrative record: the pharmacist had written “verified” on questionable prescriptions. The DEA rejected this as insufficient. Not fraudulent. Not fabricated. Insufficient. A single word where a paragraph was required.

Neumann’s Pharmacy, in a 2025 decision, confirmed that undocumented, post hoc justifications carry no weight with the Agency. A pharmacist who claims to have verified a prescription by telephone, without a contemporaneous record of that call, the date, the name of the individual contacted, the specific information obtained, the clinical rationale for the dispensing decision, has not verified anything. The claim evaporates the moment the investigator asks to see the documentation.

Eleven of the fourteen pharmacy revocation orders published in the Federal Register between January 2024 and spring of 2025 cite documentation failures as the primary or contributing basis for action. The pattern is not about pharmacists dispensing controlled substances in bad faith. It is about pharmacists who dispensed in good faith and could not prove it afterward.

The Walgreens settlement in April 2025 resolved allegations involving millions of improperly filled prescriptions, including what the DEA terms the “trinity cocktail,” an opioid prescribed with a benzodiazepine and a muscle relaxant. The settlement reached $300 million. But what the figure obscures is this: the corporate resolution does not insulate the pharmacists who filled those prescriptions. Individual criminal liability is a separate matter, proceeding on its own timeline, indifferent to whatever sum the corporation agreed to pay.

I have spoken with pharmacists who filled prescriptions at chain locations under production quotas and metrics that rewarded volume. They did not understand, until the investigation began, that the liability was theirs alone. Corporate policy encouraged speed. The Controlled Substances Act demands deliberation.

There is no statute that reconciles the two. There probably never will be.

The Records They Will Examine

A DEA inspection is, at its foundation, an audit of controlled substance accountability. The investigators will trace your biennial inventories, incoming invoices, DEA Form 222 orders for Schedule II substances, CSOS electronic ordering records, destruction and disposal logs documented on Form 41, theft and loss reports submitted on Form 106, and the prescriptions themselves. The process begins with your most recent inventory count and follows every controlled substance unit forward: what arrived, what was dispensed, what remains on the shelf. The arithmetic must balance. Where it does not, the discrepancy becomes the center of the inquiry.

Records must be maintained for a minimum of two years and must be readily retrievable. The phrase does not mean somewhere in the filing cabinet. It means producible upon request, organized, complete, legible. A pharmacist who spends forty minutes locating last quarter’s Schedule II invoices while an investigator waits in the dispensing area has communicated something about the pharmacy’s compliance posture without saying a word.

What has changed since 2024, and what something like forty percent of the independent pharmacies we have consulted with have not yet absorbed, is the standard for documenting red flag resolution. It is no longer adequate to note that a concern was identified and resolved. The contemporaneous record must specify the nature of the concern, the steps taken to investigate, the name of the person contacted (not “the prescriber’s office” but the individual), the information obtained, and the reasoning that led the pharmacist to conclude the prescription satisfied the corresponding responsibility standard. The record must exist at the time of dispensing. A notation added weeks later, even if accurate, is diminished.

There is a particular silence in a pharmacy after the last customer has left and before the closing count begins. That silence is where compliance either lives or does not. The records the DEA examines are, in the end, a written record of whether anyone was paying attention during that silence, or whether the prescriptions moved through the system without resistance.

What Follows the Inspection

The investigator’s departure does not conclude the matter. The DEA may issue a Letter of Admonition, impose a Memorandum of Agreement with compliance conditions, or, where the Agency considers the violations serious or systemic, serve an Order to Show Cause proposing revocation of your registration. An immediate suspension accompanies the Order to Show Cause where the DEA determines your continued registration poses an imminent danger to public health.

Civil penalties, adjusted in February 2024, are $18,759 per recordkeeping violation and $80,850 per prescription violation. A pattern of flagrant violations carries a ceiling of $1,951,000. These figures address only civil exposure. Criminal prosecution, state board disciplinary proceedings, and False Claims Act liability where Medicare or Medicaid reimbursement was involved each proceed on separate tracks.

One piece of advice has been repeated by every former DEA investigator I have heard address a pharmacy audience in the past three years: do not surrender your registration. The pressure to do so in the moment can be considerable. Investigators may suggest leniency will follow. It will not. A voluntary surrender for cause is permanent. The registration, once relinquished, does not return.

The Conversation That Should Have Happened Earlier

Every pharmacy that holds a DEA registration should maintain a written protocol for the moment an investigator appears: whom to contact, who is authorized to interact with the DEA, what the staff should and should not say. The protocol belongs in the same location as the biennial inventory, reviewed with the same regularity, understood by every person who works behind the counter. Most pharmacies do not have one. The ones that do tend to have drafted it after an inspection, not before.

Preparation is not a defensive posture. It is the standard of practice the DEA itself articulates. The first call to an attorney is where clarity begins, and clarity, in an enforcement environment that penalizes the undocumented and the imprecise, is the only protection that holds.

We take those calls. The conversation itself costs nothing. What it prevents is the subject of this article.